Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Pricing
Podcast Image

60 Minutes

02/02/2025: What Will Mitch Do?, Robert Lighthizer, A Psychedelic Journey

03 Feb 2025

Description

Now that President Donald Trump has retaken the White House and is shaking up Washington with an onslaught of executive orders and controversial nominees for his Cabinet, correspondent Lesley Stahl profiles the longest-serving Senate party leader, Mitch McConnell, on his life, legacy and what he will do next since stepping down from Senate leadership. Tariffs were a signature of President Trump’s campaign and are now part of his economic agenda promising to protect American trade and recover manufacturing jobs. Correspondent Scott Pelley interviews Robert Lighthizer, the top trade negotiator during Trump’s first term who continues to be an informal advisor and confidant of the president. Last year, the Veterans Administration announced it would begin funding clinical trials to explore the use of psychedelic drugs for treating post-traumatic stress disorder, depression and addiction. However, these trials are small, and even if successful, it will likely be years before veterans can access psychedelics at the VA. Many U.S. veterans struggling with PTSD aren’t waiting. Thousands of veterans are traveling overseas seeking relief at psychedelic retreats where these substances are legal to use, mostly in indigenous ceremonies. Correspondent Anderson Cooper follows nine veterans on a psychedelic journey to the west coast of Mexico, where they hope to find healing. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Audio
Featured in this Episode

No persons identified in this episode.

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes
🗳️ Sign in to Upvote

Popular episodes get transcribed faster

Comments

There are no comments yet.

Please log in to write the first comment.